Reporting performance of prognostic models in cancer: A review

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Mallett, Susan ^a   Royston, Patrick ^b   Waters, Rachel ^a   Dutton, Susan ^a   Altman, Douglas G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; CANCER SURVIVAL; HAZARD RATIO; HIGH RISK POPULATION; MALIGNANT NEOPLASTIC DISEASE; OUTCOMES RESEARCH; PERFORMANCE MEASUREMENT SYSTEM; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUALITY CONTROL; REPRODUCIBILITY; STATISTICAL MODEL; VALIDATION PROCESS; EVALUATION; HUMAN; NEOPLASM; REVIEW; STATISTICS;

EVALUATION STUDIES AS TOPIC; HUMANS; NEOPLASMS; PROGNOSIS; STATISTICS AS TOPIC;

EID: 77950389784     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-21     Document Type: Article

References (102)

1. Hemingway H. Prognosis research: why is Dr. Lydgate still waiting?. J Clin Epidemiol 2006, 59:1229-1238. 10.1016/j.jclinepi.2006.02.005, 17098565.
2. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how?. BMJ 2009, 338:b375. 10.1136/bmj.b375, 19237405.
3. Steyerberg EW. Clinical prediction models 2008, New York: Springer.
4. Harrell FE. Regression Modeling Strategies:with applications to linear models, logistic regression and survival analysis 2001, New York: Springer-Verlag.
5. Royston P, Sauerbrei W. Multivariable model-building: A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables 2008, John Wiley & Sons Ltd; Chichester UK, 1.
6. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. 10.1002/sim.2929, 17569110.
7. Mallett S, Royston P, Dutton S, Waters R, Altman D. Reporting methods in studies developing prognostic models in cancer: a review. BMC Medicine 2010, 8:20. 10.1186/1741-7015-8-20, 20353578.
8. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005, 173:1496-1501. 10.1097/01.ju.0000154351.37249.f0, 15821467.
9. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005, 23:175-183. 10.1200/JCO.2005.04.177, 15625371.
10. Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N, Munarriz B, Martin M. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat 2005, 94:265-272. 10.1007/s10549-005-9013-y, 16254686.
11. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-841. 10.1200/JCO.2005.05.179, 15681528.
12. North RB, LaRocca VR, Schwartz J, North CA, Zahurak M, Davis RF, McAfee PC. Surgical management of spinal metastases: analysis of prognostic factors during a 10-year experience. J Neurosurg Spine 2005, 2:564-573. 10.3171/spi.2005.2.5.0564, 15945430.
13. Smith BD, Smith GL, Cooper DL, Wilson LD. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol 2005, 23:3390-3395. 10.1200/JCO.2005.08.137, 15908651.
14. Solsona E, Iborra I, Dumont R, Rubio J, Casanova JL, Almenar S. Risk groups in patients with bladder cancer treated with radical cystectomy: statistical and clinical model improving homogeneity. J Urol 2005, 174:1226-1230. 10.1097/01.ju.0000173920.31824.2f, 16145375.
15. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005, 174:1759-1763. 10.1097/01.ju.0000177487.64651.3a, 16217278.
16. Liao CS, Yang KC, Yen MF, Hsiu-Hsi CT. Time-varying predictors for clinical surveillance of small hepatocellular carcinoma. Cancer 2005, 11:226-233.
17. Khaled H, El Hattab O, Moneim DA, Kassem HA, Morsi A, Sherif G, Darwish T, Gaafar R. A prognostic index (bladder prognostic index) for bilharzial-related invasive bladder cancer. Urol Oncol 2005, 23:254-260.
18. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005, 23:7005-7012. 10.1200/JCO.2005.01.867, 2231088, 16192588.
19. Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Jpn J Clin Oncol 2005, 35:514-519. 10.1093/jjco/hyi143, 16199422.
20. Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer 2005, 103:320-328. 10.1002/cncr.20756, 15593360.
21. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005, 23:9304-9311. 10.1200/JCO.2005.02.5023, 16361629.
22. Stracci F, La Rosa F, Falsettini E, Ricci E, Aristei C, Bellezza G, Bolis GB, Fenocchio D, Gori S, Rulli A, Mastrandrea V. A population survival model for breast cancer. Breast 2005, 14:94-102. 10.1016/j.breast.2004.08.011, 15767178.
23. Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M. Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol 2005, 174:2120-2123. 10.1097/01.ju.0000181801.22474.8b, 16280740.
24. Kato H, Yoshimatsu K, Ishibashi K, Watanabe K, Shiozawa S, Tsuchiya A, Yamada R, Sakamoto T, Haga S. A new staging system for colorectal carcinoma with liver metastasis. Anticancer Res 2005, 25:1251-1255.
25. Truong PT, Lesperance M, Culhaci A, Kader HA, Speers CH, Olivotto IA. Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 2005, 62:175-182. 10.1016/j.ijrobp.2004.09.013, 15850919.
26. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, Corradini P, Rosti G, Ringden O, Bregni M, Niederwieser D. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005, 104:2099-2103. 10.1002/cncr.21477, 16220555.
27. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 2005, 35:557-566. 10.1038/sj.bmt.1704789, 15665852.
28. Claude L, Perol D, Ray-Coquard I, Petit T, Blay JY, Carrie C, Bachelot T. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 2005, 76:334-339. 10.1016/j.radonc.2005.06.004, 16024123.
29. Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat MC, Daures JP, Pujol JL. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005, 93:1098-1105. 10.1038/sj.bjc.6602836, 2361505, 16234816.
30. Molica S, Mauro FR, Callea V, Gentile M, Giannarelli D, Lopez M, Lauria F, Rotoli B, Montanaro M, Cortelezzi A, Liso V, Mandelli F, Foa R. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005, 46:553-560. 10.1080/10428190400029965, 16032778.
31. Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005, 65:279-283. 10.1016/j.urology.2004.09.021, 15708038.
32. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48-51.
33. Steyerberg EW, Homs MY, Stokvis A, Essink-Bot ML, Siersema PD. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc 2005, 62:333-340. 10.1016/S0016-5107(05)01587-7, 16111947.
34. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005, 173:1938-1942. 10.1097/01.ju.0000158155.33890.e7, 15879786.
35. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Lelie J, Boogaerts MA, Lowenberg B. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23:1969-1978. 10.1200/JCO.2005.06.027, 15632409.
36. Langendijk JA, Slotman BJ, Waal I, Doornaert P, Berkof J, Leemans CR. Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer 2005, 104:1408-1417. 10.1002/cncr.21340, 16130134.
37. Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. Br J Dermatol 2005, 153:118-124. 10.1111/j.1365-2133.2005.06676.x, 16029336.
38. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya A, Nelson M, Stebbing J. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005, 143:265-273.
39. Mariani L, Miceli R, Lusa L, Di Bartolomeo M, Bozzetti F. A modified prognostic score for patients with curatively resected gastric cancer. Tumori 2005, 91:221-226.
40. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, Maase H. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005, 93:273-278. 10.1038/sj.bjc.6602702, 2361564, 16052222.
41. Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 2005, 87:698-703. 10.1302/0301-620X.87B5.15185, 15855375.
42. Aa MN, van Leenders GJ, Steyerberg EW, van Rhijn BW, Jobsis AC, Zwarthoff EC, Kwast TH. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 2005, 36:981-986. 10.1016/j.humpath.2005.06.017, 16153461.
43. Saisho T, Okusaka T, Ueno H, Morizane C, Okada S. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Hepatogastroenterology 2005, 52:1654-1658.
44. Rubio L, Vera-Sempere FJ, Lopez-Guerrero JA, Padilla J, Moreno-Baylach MJ. A risk model for non-small cell lung cancer using clinicopathological variables, angiogenesis and oncoprotein expression. Anticancer Res 2005, 25:497-504.
45. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG, Gronchi A. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005, 103:402-408. 10.1002/cncr.20778, 15578681.
46. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Makuuchi M, Omata M. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005, 54:419-425. 10.1136/gut.2003.035055, 1774402, 15710994.
47. Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg 2005, 200:378-392. 10.1016/j.jamcollsurg.2004.10.031, 15737848.
48. Shulman MJ, Benaim EA. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma. Cancer 2005, 103:2280-2286. 10.1002/cncr.21054, 15844202.
49. Gronlund B, Christensen IJ, Bulow-Lehnsby AL, Engelholm SA, Hansen HH, Hogdall C. Recurrent epithelial ovarian cancer: validation and improvement of an established prognostic index. Eur J Obstet Gynecol Reprod Biol 2005, 123:98-106. 10.1016/j.ejogrb.2005.03.011, 15896897.
50. Hasebe T, Sasaki S, Imoto S, Wada N, Ishii G, Ochiai A. Primary tumour-vessel tumour-nodal tumour classification for patients with invasive ductal carcinoma of the breast. Br J Cancer 2005, 92:847-856. 10.1038/sj.bjc.6602353, 2361891, 15756255.
51. Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005, 11:8669-8673. 10.1158/1078-0432.CCR-05-1668, 16361552.
52. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, Glass A, Zehnbauer BA, Lister K, Parwaresch R. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 2005, 18:1067-1078. 10.1038/modpathol.3800388, 15920556.
53. Froehner M, Koch R, Litz RJ, Haase M, Klenk U, Oehlschlaeger S, Baretton GB, Wirth MP. Comparison of tumor- and comorbidity-related predictors of mortality after radical prostatectomy. Scand J Urol Nephrol 2005, 39:449-454. 10.1080/00365590510031174, 16303719.
54. Nathan SS, Healey JH, Mellano D, Hoang B, Lewis I, Morris CD, Athanasian EA, Boland PJ. Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care. J Clin Oncol 2005, 23:6072-6082. 10.1200/JCO.2005.08.104, 16135474.
55. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Stat Med 1989, 8:771-783. 10.1002/sim.4780080702, 2672226.
56. Sauerbrei W, Royston P. Modelling to extract more information from clinical trials data: On some roles for the bootstrap. Stat Med 2007, 26:4989-5001. 10.1002/sim.2954, 17607706.
57. Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003, 56:441-447. 10.1016/S0895-4356(03)00047-7, 12812818.
58. Steyerberg EW. Study design for prediction models. Clinical Prediction Models 2008, Chapter 3. New York: Springer.
59. Altman DG. Prognostic models: a methodological framework and review of models for breast cancer. Cancer Invest 2009, 27:235-243. 10.1080/07357900802572110, 19291527.
60. Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 2008, 27:191-195. 10.1002/sim.2987, 17671959.
61. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86:829-835. 10.1093/jnci/86.11.829, 8182763.
62. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006, 25:127-141. 10.1002/sim.2331, 16217841.
63. Ragland DR. Is there really a conceptual difference in choosing the cutpoint for dichotomizing outcome and predictor variables?. Epidemiology 1993, 4:276. 10.1097/00001648-199305000-00015, 8512995.
64. Ewald B. Post hoc choice of cut points introduced bias to diagnostic research. J Clin Epidemiol 2006, 59:798-801. 10.1016/j.jclinepi.2005.11.025, 16828672.
65. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY. Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. Arch Intern Med 2008, 168:2304-2310. 10.1001/archinte.168.21.2304, 19029492.
66. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ 2009, 338:b605. 10.1136/bmj.b605, 19477892.
67. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004, 23:723-748. 10.1002/sim.1621, 14981672.
68. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med 1999, 18:2529-2545. 10.1002/(SICI)1097-0258(19990915/30)18:17/18<2529::AID-SIM274>3.0.CO; 2-5, 10474158.
69. Altman DG, Royston P. What do we mean by validating a prognostic model?. Stat Med 2000, 19:453-473. 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5, 10694730.
70. Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. Stat Med 2000, 19:1997-2014. 10.1002/1097-0258(20000815)19:15<1997::AID-SIM511>3.0.CO;2-C, 10900448.
71. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006, 26:565-574. 10.1177/0272989X06295361, 2577036, 17099194.
72. Steyerberg EW. Evaluation of performance. Clinical Prediction Models 2008, Chapter 15. New York: Springer.
73. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 2009, 338:b606. 10.1136/bmj.b606, 19502216.
74. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4, 8668867.
75. van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival models. Stat Med 2000, 19:3401-3415. 10.1002/1097-0258(20001230)19:24<3401::AID-SIM554>3.0.CO;2-2, 11122504.
76. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999, 130:515-524.
77. Steyerberg EW. Validation of prediction models. Clinical Prediction Models Chapter 17 2008, Chapter 17. New York: Springer.
78. Toll DB, Janssen KJ, Vergouwe Y, Moons KG. Validation, updating and impact of clinical prediction rules: a review. J Clin Epidemiol 2008, 61:1085-1094. 10.1016/j.jclinepi.2008.04.008, 19208371.
79. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'Brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 2006, 134:58-60. 10.1111/j.1365-2141.2006.06106.x, 16803568.
80. Chow E, Harris K, Fung K. Successful validation of a survival prediction model in patients with metastases in the spinal column. Int J Radiat Oncol Biol Phys 2006, 65:1522-1527.
81. May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007, 178:1957-1962. 10.1016/j.juro.2007.07.043, 17868719.
82. Jonkman A, Kaanders JH, Terhaard CH, Hoebers FJ, Ende PL, Wijers OB, Verhoef LC, de Jong MA, Leemans CR, Langendijk JA. Multicenter validation of recursive partitioning analysis classification for patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:119-125.
83. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer 2007, 14:29-42. 10.1677/erc.1.01284, 17395973.
84. Jacot W, Colinet B, Bertrand D, Lacombe S, Bozonnat MC, Daures JP, Pujol JL. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 2008, 19:1458-1464. 10.1093/annonc/mdn064, 18356134.
85. Cooperberg MR. Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer 2008, 113:3062-3066. 10.1002/cncr.23920, 18855919.
86. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 2008, 72:396-400. 10.1016/j.urology.2007.11.165, 18372031.
87. Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol 2008, 23:445-452. 10.1111/j.1440-1746.2007.05075.x, 17683486.
88. Leithner A, Radl R, Gruber G, Hochegger M, Leithner K, Welkerling H, Rehak P, Windhager R. Predictive value of seven preoperative prognostic scoring systems for spinal metastases. Eur Spine J 2008, 17:1488-1495. 10.1007/s00586-008-0763-1, 2583181, 18787846.
89. Schroeck FR, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?. BJU Int 2009, 103:603-608. 10.1111/j.1464-410X.2008.08118.x, 2753544, 19021608.
90. Eggener SE, Vickers AJ, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ, Scardino PT. Comparison of models to predict clinical failure after radical prostatectomy. Cancer 2009, 115:303-310. 10.1002/cncr.24016, 2740715, 19025977.
91. Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. Eur J Cancer 2009, 45:1630-1639. 10.1016/j.ejca.2008.12.025, 19157858.
92. Huo TI, Hsia CY, Huang YH, Lin HC, Lee PC, Lui WY, Chiang JH, Chiou YY, Loong CC, Lee SD. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems. J Clin Gastroenterol 2009, 43:773-781. 10.1097/MCG.0b013e31818dd962, 19262404.
93. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol 2001, 54:979-985. 10.1016/S0895-4356(01)00372-9, 11576808.
94. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996, 49:907-916. 10.1016/0895-4356(96)00025-X, 8699212.
95. Leushuis E, Steeg JW, Steures P, Bossuyt PM, Eijkemans MJ, Veen F, Mol BW, Hompes PG. Prediction models in reproductive medicine: a critical appraisal. Hum Reprod Update 2009, 15:537-552. 10.1093/humupd/dmp013, 19435779.
96. Mikolajczyk RT, DiSilvestro A, Zhang J. Evaluation of logistic regression reporting in current obstetrics and gynecology literature. Obstet Gynecol 2008, 111:413-419.
97. Mushkudiani NA, Hukkelhoven CW, Hernandez AV, Murray GD, Choi SC, Maas AI, Steyerberg EW. A systematic review finds methodological improvements necessary for prognostic models in determining traumatic brain injury outcomes. J Clin Epidemiol 2008, 61:331-343. 10.1016/j.jclinepi.2007.06.011, 18313557.
98. Ottenbacher KJ, Ottenbacher HR, Tooth L, Ostir GV. A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. J Clin Epidemiol 2004, 57:1147-1152. 10.1016/j.jclinepi.2003.05.003, 15567630.
99. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 2009, 339:b2584. 10.1136/bmj.b2584, 2714681, 19584409.
100. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009, 9:57. 10.1186/1471-2288-9-57, 2727536, 19638200.
101. Vergouwe Y, Royston P, Moons KG, Altman DG. Development and validation of a prediction model with missing predictor data: a practical approach. J Clin Epidemiol 2009, 63:205-214. 10.1016/j.jclinepi.2009.03.017, 19596181.
102. Janssen KJ, Vergouwe Y, Donders RT, Harrell FE, Chen Q, Grobbee DE, Moons KG. Dealing with missing predictor variables when applying clinical prediction models. Clinical Chemistry 2009,